ARTICLE | Clinical News
Zelboraf vemurafenib: Phase II started
October 21, 2013 7:00 AM UTC
The Melanoma Research Foundation (MRF) Breakthrough Consortium began an open-label, U.S. Phase II trial to evaluate 15 mg/kg IV Avastin bevacizumab every 3 weeks plus 960 mg oral Zelboraf twice daily...